Monrovia Post Acute: Care Plan Violations - Duarte, CA
DUARTE, CA - A recent state inspection at Monrovia Post Acute found the facility failed to properly assess a resident's neurological condition and develop an appropriate care plan for managing Parkinson's disease medication, potentially putting the resident at risk for adverse medication events.
Assessment Documentation Errors Discovered
The May 15, 2025 inspection revealed significant issues with how staff documented and tracked a resident's medical conditions. The resident, who has bipolar disorder, dementia, and Parkinson's disease, was not properly identified as having Parkinson's disease in the facility's official assessment records, despite clear medical evidence of the condition.
During the inspection, the resident was observed sitting up in bed with noticeable tremors in both hands and arms. "Excuse me shaking, I have Parkinson's," the resident told inspectors, clearly aware of their condition.
Medical records showed the resident had been prescribed Sinemet, a combination medication containing levodopa and carbidopa specifically used to treat Parkinson's disease symptoms. The medication was ordered to be given three times daily through a gastrostomy tube. However, the facility's Minimum Data Set (MDS) assessment - a comprehensive evaluation required for all nursing home residents - failed to include Parkinson's disease under the neurological conditions section.
Medication Management and Monitoring Gaps
The inspection uncovered concerning issues with medication continuity and follow-up care. A neurologist had evaluated the resident in January 2025 for tremors and initiated a trial of Levodopa medication. "Given that Levodopa may worsen or precipitate behavior disturbances, I discussed with staff to contact me right away if there are any concerns for adverse reactions to Levodopa," the neurologist documented in consultation notes.
Records showed the Sinemet medication was started on January 27, 2025, then discontinued on May 7, 2025, and restarted the following day on May 8, 2025. However, the facility never contacted the neurologist for follow-up monitoring, despite his specific instructions.
The neurologist told inspectors during a phone interview that he had only seen the resident once and "there was no follow-up by MD 1 because the facility did not contact MD 1 again about Resident 2." He explained that follow-up on the Levodopa trial should have occurred within a day or two after the resident started taking the medication.
Medical Significance and Risk Factors
Accurate assessment and documentation of neurological conditions like Parkinson's disease is critical for resident safety. Sinemet, while effective for managing Parkinson's symptoms, carries significant risks that require careful monitoring. The medication can cause dyskinesia - abnormal, involuntary, and repetitive movements - as well as behavioral disturbances, particularly in residents with existing cognitive impairment.
For residents with dementia, like this individual who was assessed as cognitively severely impaired, the risks are amplified. The combination of Parkinson's disease, bipolar disorder, and dementia creates a complex medical picture requiring specialized attention and regular physician oversight.
When medications like Sinemet are prescribed for neurological conditions, healthcare standards require comprehensive care planning that includes monitoring protocols, potential side effects, and clear communication pathways with specialists. The facility's failure to maintain proper documentation could lead to medication errors, missed adverse reactions, or inappropriate treatment decisions by staff unfamiliar with the resident's complete medical history.